


FIPI hydrochloride

Cat. No.:	HY-12807A
CAS No.:	1781834-93-2
Molecular Formula:	C ₂₃ H ₂₅ ClFN ₅ O ₂
Molecular Weight:	457.93
Target:	Phospholipase; Autophagy
Pathway:	Metabolic Enzyme/Protease; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FIPI (5-Fluoro-2-indolyl des-chlorohalopemide) hydrochloride, a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC ₅₀ s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI hydrochloride inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI hydrochloride has the potential for autoimmunity and cancer metastasis research ^{[1][2][3]} .
IC₅₀ & Target	IC50: 25 nM (PLD1), 20 nM (PLD2)

CUSTOMER VALIDATION

- Anal Chem. 2018 Jun 5;90(11):6742-6748.
- J Cell Sci. 2018 Mar 16;131(6). pii: jcs207217.
- Patent. US20230050888A1.
- Nanoscale Res Lett. 2019 Apr 18;14(1):138.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Monovich L, et al. Optimization of halopemide for phospholipase D2 inhibition. *Bioorg Med Chem Lett*. 2007 Apr 15;17(8):2310-1.
- [2]. Claudia Dall'Armi, et al. The phospholipase D1 pathway modulates macroautophagy. *Nat Commun*. 2010;1:142.
- [3]. Su W, et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. *Mol Pharmacol*. 2009 Mar;75(3):437-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA